PTX3 and pulmonary fibrosis: Our results of αPTX3i safety, therapeutic efficiency in pulmonary fibrosis and compared with pirfenidone and nintedanib support that targeting PTX3 may be an effective strategy for lung injury‐induced fibrosis.